Levodopa in the treatment of Parkinson's disease: current controversies.

CW, Olanow; Y, Agid; Y, Mizuno; A, Albanese; U, Bonuccelli; P, Damier; Yebenes J, De; O, Gershanik; M, Guttman; F, Grandas; M, Hallett; O, Hornykiewicz; P, Jenner; R, Katzenschlager; WJ, Langston; P, LeWitt; E, Melamed; MA, Mena; PP, Michel; C, Mytilineou; JA, Obeso; W, Poewe; N, Quinn; R, Raisman-Vozari; AH, Rajput; O, Rascol; C, Sampaio; F, Stocchi

doi:10.1002/mds.20243

Public

Levodopa in the treatment of Parkinson's disease: current controversies.

Shared by NobleBlocks on Sep 1, 2004 • 12:00 AM UTC

Authors:

Olanow CW

Agid Y

Mizuno Y

Abstract

Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the "gold standard" against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor complications...

Discussions